Reuters Health Report: September 11, 2017

Click to View in Browser Monday, September 11, 2017 Roche shares hit by trial flops, fears over biosimilar defense ZURICH (Reuters) - Roche shares fell in early trading on Monday after trial failures added to the Swiss drugmaker's challenge of replacing patent-expired medicines with lucrative new drugs. Sanofi and Regeneron score asthma hit with dupilumab PARIS (Reuters) - Sanofi and Regeneron's biotech drug dupilumab scored a hit in treating severe asthma, clinical trial data showed on Monday, raising competition in an expected multibillion-dollar market. J&J unit ends hepatitis C drug development in crowded market (Reuters) - Janssen Sciences Ireland UC, a unit of Johnson & Johnson, said it would discontinue further development of its hepatitis C research, citing increased availability of a number of effective hepatitis C therapies. Novartis posts a win, Roche a flop in skin cancer trials ZURICH/MADRID (Reuters) - Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient group. After melanoma surgery, Bristol's Opdivo offers new care standard MADRID (Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients who have had surgery to remove disease, researchers reported on Monday. AstraZeneca rebuilds cancer drug hopes with new lung data MADRID (Reuters) - Two AstraZeneca drugs tackling lung cancer in different ways delivered impressive clinical results on Saturday, helping the British group offset July's big clinical trial setback in the disease. Over 500 dead as Congo cholera epidemic spreads: WHO KINSHASA (Reuters) - More than 500 people have died so far in a cholera epidemic that is sweeping the Democratic Republic of Congo, the World Health Organization (WHO) said. Lilly takes on Pfizer, Novartis with new breast cancer drug data NEW YORK/MADRID (Reuters) - Eli Lilly staked its claim for a slice of sales in a new class of breast cancer drugs on Sunday as clinical data showed adding its medicine abemaciclib to standard therapy reduced the risk of disease progression by 46 percent. Bristol's drug cocktail cuts kidney cancer death risk 37 percent MADRID (Reuters) - A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients, data from a closely watched clinical trial showed on Sunday. Cancer mutation gains ground as test for immunotherapy drugs MADRID (Reuters) - Scientists are stepping up the hunt for better diagnostic tests to predict if cancer patients will benefit from costly modern immunotherapy drugs, which are transforming cancer care but remain a hit-and-miss affair. Related Video Hurricane Irma seen from space Caribbean decimated, Floridians flee as Irma approaches A quick-fix on the day's news delivered when you want it. Register Today A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today » » MORE NEWSLETTERS - 3 Times Square New York, NY 10036 USA © Copyright 2017 Thomson Reuters Ensure delivery of Reuters Newsmails, add newsletters@email.reuters.com to your address book. Subscribe to other Reuters newsletters. Unsubscribe from this newsletter. Follow us on Twitter Friend us on Facebook